Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial

The Lancet Respiratory Medicine

Volumn 7, Issue 2, 2019, Pages 154-162

  Matthay, Michael A ^a   Calfee, Carolyn S ^a   Zhuo, Hanjing ^a   Thompson, B Taylor ^b   Wilson, Jennifer G ^c   Levitt, Joseph E ^d   Rogers, Angela J ^d   Gotts, Jeffrey E ^a   Wiener Kronish, Jeanine P ^b   Bajwa, Ednan K ^b   Donahoe, Michael P ^e   McVerry, Bryan J ^e   Ortiz, Luis A ^f   Exline, Matthew ^g   Christman, John W ^g   Abbott, Jason ^a   Delucchi, Kevin L ^a   Caballero, Lizette ^a   McMillan, Melanie ^a   McKenna, David H ^h   Liu, Kathleen D ^a   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c STANFORD UNIVERSITY   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^h UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; MORTALITY RATE; MULTICENTER STUDY; OXYGEN TENSION; PHASE 2 CLINICAL TRIAL; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; AGED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; HOSPITAL MORTALITY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NONPARAMETRIC TEST; PATIENT SAFETY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ADULT; AGED; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HOSPITAL MORTALITY; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT SAFETY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RESPIRATORY DISTRESS SYNDROME, ADULT; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 85060547818     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(18)30418-1     Document Type: Article

References (31)

1. Matthay, MA, Ware, LB, Zimmerman, GA, The acute respiratory distress syndrome. J Clin Invest 122 (2012), 2731–2740.
2. Thompson, BT, Chambers, RC, Liu, KD, Acute respiratory distress syndrome. N Engl J Med 377 (2017), 562–572.
3. Bellani, G, Laffey, JG, Pham, T, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 315 (2016), 788–800.
4. Matthay, MA, Pati, S, Lee, JW, Concise review: mesenchymal stem (stromal) cells: biology and preclinical evidence for therapeutic potential for organ dysfunction following trauma or sepsis. Stem Cells 35 (2017), 316–324.
5. Walter, J, Ware, LB, Matthay, MA, Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis. Lancet Respir Med 2 (2014), 1016–1026.
6. Asmussen, S, Ito, H, Traber, DL, et al. Human mesenchymal stem cells reduce the severity of acute lung injury in a sheep model of bacterial pneumonia. Thorax 69 (2014), 819–825.
7. Lee, JW, Fang, X, Gupta, N, Serikov, V, Matthay, MA, Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci USA 106 (2009), 16357–16362.
8. Lee, JW, Krasnodembskaya, A, McKenna, DH, Song, Y, Abbott, J, Matthay, MA, Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med 187 (2013), 751–760.
9. Laffey, JG, Matthay, MA, Fifty years of research in ARDS. Cell-based therapy for acute respiratory distress syndrome. biology and potential therapeutic value. Am J Respir Crit Care Med 196 (2017), 266–273.
10. Thille, AW, Esteban, A, Fernandez-Segoviano, P, et al. Chronology of histological lesions in acute respiratory distress syndrome with diffuse alveolar damage: a prospective cohort study of clinical autopsies. Lancet Respir Med 1 (2013), 395–401.
11. Force, ADT, Ranieri, VM, Rubenfeld, GD, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 307 (2012), 2526–2533.
12. Matthay, MA, McAuley, DF, Ware, LB, Clinical trials in acute respiratory distress syndrome: challenges and opportunities. Lancet Respir Med 5 (2017), 524–534.
13. Wilson, JG, Liu, KD, Zhuo, H, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med 3 (2015), 24–32.
14. NHLBI ARDS Network. NIH NHLBI ARDS Clinical Network mechanical ventilation protocol summary. http://www.ardsnet.org/files/ventilator_protocol_2008-07.pdf. (Accessed 29 October 2018)
15. Liu, KD, Wilson, JG, Zhuo, H, et al. Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome. Ann Intensive Care, 4, 2014, 22.
16. Rosenberg, AL, Recent innovations in intensive care unit risk-prediction models. Curr Opin Crit Care 8 (2002), 321–330.
17. Wiedemann, HP, Wheeler, AP, Bernard, GR, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 354 (2006), 2564–2575.
18. Seeley, E, McAuley, DF, Eisner, M, Miletin, M, Matthay, MA, Kallet, RH, Predictors of mortality in acute lung injury during the era of lung protective ventilation. Thorax 63 (2008), 994–998.
19. Murray, JF, Matthay, MA, Luce, JM, Flick, MR, An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 138 (1988), 720–723.
20. Bhandari, V, Choo-Wing, R, Lee, CG, et al. Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. Nat Med 12 (2006), 1286–1293.
21. Parikh, SM, Angiopoietins and Tie2 in vascular inflammation. Curr Opin Hematol 24 (2017), 432–438.
22. Agrawal, A, Matthay, MA, Kangelaris, KN, et al. Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients. Am J Respir Crit Care Med 187 (2013), 736–742.
23. Calfee, CS, Gallagher, D, Abbott, J, Thompson, BT, Matthay, MA, Network, NA, Plasma angiopoietin-2 in clinical acute lung injury: prognostic and pathogenetic significance. Crit Care Med 40 (2012), 1731–1737.
24. Zinter, MS, Spicer, A, Orwoll, BO, et al. Plasma angiopoietin-2 outperforms other markers of endothelial injury in prognosticating pediatric ARDS mortality. Am J Physiol Lung Cell Mol Physiol 310 (2016), L224–L231.
25. Gutbier, B, Neuhauss, AK, Reppe, K, et al. Prognostic and pathogenic role of angiopoietin-1 and -2 in pneumonia. Am J Respir Crit Care Med 198 (2018), 220–231.
26. Kaplan, A, Sackett, K, Sumstad, D, Kadidlo, D, McKenna, DH, Impact of starting material (fresh versus cryopreserved marrow) on mesenchymal stem cell culture. Transfusion 57 (2017), 2216–2219.
27. Galipeau, J, Sensebe, L, Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell 22 (2018), 824–833.
28. Pais, FM, Sinha, P, Liu, KD, Matthay, MA, Influence of clinical factors and exclusion criteria on mortality in ards observational studies and randomized controlled trials. Respir Care 63 (2018), 1060–1069.
29. Brower, RG, Shanholtz, CB, Fessler, HE, et al. Prospective, randomized, controlled clinical trial comparing traditional versus reduced tidal volume ventilation in acute respiratory distress syndrome patients. Crit Care Med 27 (1999), 1492–1498.
30. Brower, RG, Matthay, MA, Morris, A, et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 342 (2000), 1301–1308.
31. Rubenfeld, GD, Abraham, E, When is a negative phase II trial truly negative?. Am J Respir Crit Care Med 178 (2008), 554–555.